{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:31:58Z","timestamp":1793215918156,"version":"4.5.0"},"reference-count":76,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MC-A654-5QB40"],"award-info":[{"award-number":["MC-A654-5QB40"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"Horizon 2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["101028661"],"award-info":[{"award-number":["101028661"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"Horizon 2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["101026235"],"award-info":[{"award-number":["101026235"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["224625\/Z\/21\/Z"],"award-info":[{"award-number":["224625\/Z\/21\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009655","name":"Sumitomo Pharma America Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["biologicalpsychiatryjournal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biological Psychiatry"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.biopsych.2025.10.013","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T23:27:29Z","timestamp":1761089249000},"page":"199-207","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["TAAR1 Regulates Presynaptic Dopamine Function: Evidence From Preclinical Studies and a Phase 1b Trial in Patients With Schizophrenia"],"prefix":"10.1016","volume":"100","author":[{"given":"Oliver D.","family":"Howes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke J.","family":"Vano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice E.","family":"Petty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Rutigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Els F.","family":"Halff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Veronese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Kaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Nordio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuel F.","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie J.","family":"Cragg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sridhar","family":"Natesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic J.","family":"Withers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenii A.","family":"Rabiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Dedic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Snezana","family":"Milanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Koblan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth C.","family":"Hopkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"McCutcheon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopsych.2025.10.013_bib1","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/jamapsychiatry.2019.3360","article-title":"Schizophrenia-An overview","volume":"77","author":"McCutcheon","year":"2020","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.biopsych.2025.10.013_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107704","article-title":"Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology","volume":"172","author":"Kaar","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopsych.2025.10.013_bib3","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jpsychires.2018.07.006","article-title":"The past and future of novel, non-dopamine-2 receptor therapeutics for schizophrenia: A critical and comprehensive review","volume":"108","author":"Girgis","year":"2019","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.biopsych.2025.10.013_bib4","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.neubiorev.2021.11.032","article-title":"New and emerging treatments for schizophrenia: A narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics","volume":"132","author":"Lobo","year":"2022","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.biopsych.2025.10.013_bib5","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.biopsych.2022.06.017","article-title":"Integrating the neurodevelopmental and dopamine hypotheses of schizophrenia and the role of cortical excitation-inhibition balance","volume":"92","author":"Howes","year":"2022","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2025.10.013_bib6","doi-asserted-by":"crossref","first-page":"5945","DOI":"10.3390\/ijms24065945","article-title":"Canonical and non-canonical antipsychotics\u2019 dopamine-related mechanisms of present and next generation molecules: A systematic review on translational highlights for treatment response and treatment-resistant schizophrenia","volume":"24","author":"de Bartolomeis","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.biopsych.2025.10.013_bib7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.biopsych.2016.03.2104","article-title":"Pathway-specific dopamine abnormalities in schizophrenia","volume":"81","author":"Weinstein","year":"2017","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2025.10.013_bib8","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1001\/jamapsychiatry.2023.4305","article-title":"Generalizability and out-of-sample predictive ability of associations between neuromelanin-sensitive magnetic resonance imaging and psychosis in antipsychotic-free individuals","volume":"81","author":"Wengler","year":"2024","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.biopsych.2025.10.013_bib9","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1176\/appi.ajp.20220780","article-title":"Neuromelanin-sensitive MRI as candidate marker for treatment resistance in first-episode schizophrenia","volume":"181","author":"van der Pluijm","year":"2024","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2025.10.013_bib10","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.biopsych.2024.06.013","article-title":"Mesostriatal dopaminergic circuit dysfunction in schizophrenia: A multimodal neuromelanin-sensitive magnetic resonance imaging and [18F]-DOPA positron emission tomography study","volume":"96","author":"Vano","year":"2024","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2025.10.013_bib11","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1093\/schbul\/sbx180","article-title":"Defining the locus of dopaminergic dysfunction in schizophrenia: A meta-analysis and test of the mesolimbic hypothesis","volume":"44","author":"McCutcheon","year":"2018","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.biopsych.2025.10.013_bib12","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1093\/brain\/awt264","article-title":"Midbrain dopamine function in schizophrenia and depression: A post-mortem and positron emission tomographic imaging study","volume":"136","author":"Howes","year":"2013","journal-title":"Brain"},{"key":"10.1016\/j.biopsych.2025.10.013_bib13","doi-asserted-by":"crossref","first-page":"11651","DOI":"10.1073\/pnas.91.24.11651","article-title":"Elevated dopa decarboxylase activity in living brain of patients with psychosis","volume":"91","author":"Reith","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.biopsych.2025.10.013_bib14","doi-asserted-by":"crossref","first-page":"9235","DOI":"10.1073\/pnas.93.17.9235","article-title":"Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects","volume":"93","author":"Laruelle","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.biopsych.2025.10.013_bib15","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nn804","article-title":"Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia","volume":"5","author":"Meyer-Lindenberg","year":"2002","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.biopsych.2025.10.013_bib16","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1001\/jamapsychiatry.2014.2414","article-title":"Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: A positron emission tomographic functional magnetic resonance imaging study","volume":"72","author":"Slifstein","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.biopsych.2025.10.013_bib17","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1073\/pnas.94.6.2569","article-title":"Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method","volume":"94","author":"Breier","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.biopsych.2025.10.013_bib18","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.biopsych.2011.10.009","article-title":"Increased stress-induced dopamine release in psychosis","volume":"71","author":"Mizrahi","year":"2012","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2025.10.013_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41398-019-0665-5","article-title":"Correction: Differential transcriptional response following glucocorticoid activation in cultured blood immune cells: A novel approach to PTSD biomarker development","volume":"10","author":"Breen","year":"2020","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.biopsych.2025.10.013_bib20","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.biopsych.2019.07.008","article-title":"Heterogeneity of striatal dopamine function in schizophrenia: Meta-analysis of variance","volume":"87","author":"Brugger","year":"2020","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2025.10.013_bib21","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1176\/appi.ajp.2011.11010160","article-title":"Dopamine synthesis capacity before onset of psychosis: A prospective [18F]-DOPA PET imaging study","volume":"168","author":"Howes","year":"2011","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2025.10.013_bib22","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/mp.2011.20","article-title":"Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: A PET study","volume":"16","author":"Howes","year":"2011","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2025.10.013_bib23","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.biopsych.2012.11.017","article-title":"Presynaptic striatal dopamine dysfunction in people at ultra-high risk for psychosis: Findings in a second cohort","volume":"74","author":"Egerton","year":"2013","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2025.10.013_bib24","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0006-3223(99)00067-0","article-title":"Increased dopamine transmission in schizophrenia: Relationship to illness phases","volume":"46","author":"Laruelle","year":"1999","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2025.10.013_bib25","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.biopsych.2018.07.003","article-title":"The effects of antipsychotic treatment on presynaptic dopamine synthesis capacity in first-episode psychosis: A positron emission tomography study","volume":"85","author":"Jauhar","year":"2019","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2025.10.013_bib26","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1038\/s41380-021-01108-y","article-title":"Striatal dopaminergic alterations in individuals with copy number variants at the 22q11.2 genetic locus and their implications for psychosis risk: A [18F]-DOPA PET study","volume":"28","author":"Rogdaki","year":"2023","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2025.10.013_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.pneurobio.2022.102265","article-title":"Dopaminergic alterations in populations at increased risk for psychosis: A systematic review of imaging findings","volume":"213","author":"van Hooijdonk","year":"2022","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.biopsych.2025.10.013_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222413185","article-title":"Therapeutic potential of TAAR1 agonists in schizophrenia: Evidence from preclinical models and clinical studies","volume":"22","author":"Dedic","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.biopsych.2025.10.013_bib29","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.tins.2022.10.010","article-title":"Trace amine-associated receptor 1 (TAAR1) agonism as a new treatment strategy for schizophrenia and related disorders","volume":"46","author":"Halff","year":"2023","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.biopsych.2025.10.013_bib30","doi-asserted-by":"crossref","first-page":"8485","DOI":"10.1073\/pnas.1103029108","article-title":"TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity","volume":"108","author":"Revel","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.biopsych.2025.10.013_bib31","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1038\/s41386-022-01421-2","article-title":"TAAR1 dependent and independent actions of the potential antipsychotic and dual TAAR1\/5-HT1A receptor agonist SEP-363856","volume":"47","author":"Saarinen","year":"2022","journal-title":"Neuropsychopharmacol"},{"key":"10.1016\/j.biopsych.2025.10.013_bib32","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1038\/s41386-023-01779-x","article-title":"TAAR1 agonist ulotaront modulates striatal and hippocampal glutamate function in a state-dependent manner","volume":"49","author":"Yang","year":"2024","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2025.10.013_bib33","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1038\/s41593-023-01390-9","article-title":"Antipsychotic drug efficacy correlates with the modulation of D1 rather than D2 receptor-expressing striatal projection neurons","volume":"26","author":"Yun","year":"2023","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.biopsych.2025.10.013_bib34","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1038\/s41380-020-0740-6","article-title":"Reproducing the dopamine pathophysiology of schizophrenia and approaches to ameliorate it: A translational imaging study with ketamine","volume":"26","author":"Kokkinou","year":"2021","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2025.10.013_bib35","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1007\/s11307-023-01865-y","article-title":"Sub-chronic ketamine administration increases dopamine synthesis capacity in the mouse midbrain: A preclinical in vivo PET study","volume":"25","author":"Petty","year":"2023","journal-title":"Mol Imaging Biol"},{"key":"10.1016\/j.biopsych.2025.10.013_bib36","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/4419221","article-title":"Evaluation of intraperitoneal [18F]-FDOPA administration for micro-PET imaging in mice and assessment of the effect of subchronic ketamine dosing on dopamine synthesis capacity","volume":"2022","author":"Halff","year":"2022","journal-title":"Mol Imaging"},{"key":"10.1016\/j.biopsych.2025.10.013_bib37","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1124\/jpet.107.132647","article-title":"Trace amine-associated receptor 1 modulates dopaminergic activity","volume":"324","author":"Lindemann","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.biopsych.2025.10.013_bib38","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/jcbfm.2012.120","article-title":"In-vivo measurement of LDOPA uptake, dopamine reserve and turnover in the rat brain using [18F]FDOPA PET","volume":"33","author":"Walker","year":"2013","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.biopsych.2025.10.013_bib39","first-page":"1568","article-title":"Graphical analysis of 6-fluoro-L-dopa trapping: Effect of inhibition of catechol-O-methyltransferase","volume":"38","author":"Holden","year":"1997","journal-title":"J Nucl Med"},{"key":"10.1016\/j.biopsych.2025.10.013_bib40","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/00004647-200104000-00015","article-title":"A reversible tracer analysis approach to the study of effective dopamine turnover","volume":"21","author":"Sossi","year":"2001","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.biopsych.2025.10.013_bib41","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/jcbfm.1985.87","article-title":"Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data","volume":"5","author":"Patlak","year":"1985","journal-title":"Generalizations. J Cereb Blood Flow Metab"},{"key":"10.1016\/j.biopsych.2025.10.013_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/jpet.119.260281","article-title":"SEP-363856, a novel psychotropic agent with a unique, non-D2 receptor mechanism of action","volume":"371","author":"Dedic","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.biopsych.2025.10.013_bib43","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.neuropharm.2014.02.007","article-title":"Taar1-mediated modulation of presynaptic dopaminergic neurotransmission: Role of D2 dopamine autoreceptors","volume":"81","author":"Leo","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopsych.2025.10.013_bib44","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1056\/NEJMoa1911772","article-title":"A non-D2-receptor-binding drug for the treatment of schizophrenia","volume":"382","author":"Koblan","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.biopsych.2025.10.013_bib45","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.neuroimage.2009.12.058","article-title":"The test\u2013retest reliability of 18F-DOPA PET in assessing striatal and extrastriatal presynaptic dopaminergic function","volume":"50","author":"Egerton","year":"2010","journal-title":"Neuroimage"},{"key":"10.1016\/j.biopsych.2025.10.013_bib46","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1177\/0271678X231168687","article-title":"An automatic analysis framework for FDOPA PET neuroimaging","volume":"43","author":"Nordio","year":"2023","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.biopsych.2025.10.013_bib47","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1097\/00004647-199911000-00003","article-title":"Multiresolution analysis of emission tomography images in the wavelet domain","volume":"19","author":"Turkheimer","year":"1999","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.biopsych.2025.10.013_bib48","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.neuroimage.2011.10.025","article-title":"SPM: A history","volume":"62","author":"Ashburner","year":"2012","journal-title":"Neuroimage"},{"issue":"suppl 1","key":"10.1016\/j.biopsych.2025.10.013_bib49","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1093\/schbul\/sbv167","article-title":"Dose equivalents for antipsychotic drugs: The DDD method","volume":"42","author":"Leucht","year":"2016","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.biopsych.2025.10.013_bib50","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamapsychiatry.2017.2943","article-title":"A test of the transdiagnostic dopamine hypothesis of psychosis using positron emission tomographic imaging in bipolar affective disorder and schizophrenia","volume":"74","author":"Jauhar","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.biopsych.2025.10.013_bib51","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.npp.1301147","article-title":"Linking the PANSS, BPRS, and CGI: Clinical implications","volume":"31","author":"Leucht","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2025.10.013_bib52","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3758\/BRM.41.4.1149","article-title":"Statistical power analyses using G\u2217Power 3.1: Tests for correlation and regression analyses","volume":"41","author":"Faul","year":"2009","journal-title":"Behav Res Methods"},{"key":"10.1016\/j.biopsych.2025.10.013_bib53","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.pbb.2011.10.025","article-title":"Augmentation of methamphetamine-induced behaviors in transgenic mice lacking the trace amine-associated receptor 1","volume":"101","author":"Achat-Mendes","year":"2012","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.biopsych.2025.10.013_bib54","doi-asserted-by":"crossref","first-page":"4263","DOI":"10.1038\/s41467-019-12264-9","article-title":"Plasticity in striatal dopamine release is governed by release-independent depression and the dopamine transporter","volume":"10","author":"Condon","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.biopsych.2025.10.013_bib55","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/nn1244","article-title":"Nicotine amplifies reward-related dopamine signals in striatum","volume":"7","author":"Rice","year":"2004","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.biopsych.2025.10.013_bib56","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/34413","article-title":"Acetylcholine receptors containing the \u03b22 subunit are involved in the reinforcing properties of nicotine","volume":"391","author":"Picciotto","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.biopsych.2025.10.013_bib57","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.neuron.2012.04.038","article-title":"Striatal dopamine release is triggered by synchronized activity in cholinergic interneurons","volume":"75","author":"Threlfell","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.biopsych.2025.10.013_bib58","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.celrep.2012.05.011","article-title":"Selective activation of cholinergic interneurons enhances accumbal phasic dopamine release: Setting the tone for reward processing","volume":"2","author":"Cachope","year":"2012","journal-title":"Cell Rep"},{"key":"10.1016\/j.biopsych.2025.10.013_bib59","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1523\/JNEUROSCI.5620-09.2010","article-title":"Striatal muscarinic receptors promote activity dependence of dopamine transmission via distinct receptor subtypes on cholinergic interneurons in ventral versus dorsal striatum","volume":"30","author":"Threlfell","year":"2010","journal-title":"J Neurosci"},{"key":"10.1016\/j.biopsych.2025.10.013_bib60","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/nn1700","article-title":"RGS4-dependent attenuation of M4 autoreceptor function in striatal cholinergic interneurons following dopamine depletion","volume":"9","author":"Ding","year":"2006","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.biopsych.2025.10.013_bib61","doi-asserted-by":"crossref","first-page":"6258","DOI":"10.1523\/JNEUROSCI.1678-08.2008","article-title":"Loss of muscarinic autoreceptor function impairs long-term depression but not long-term potentiation in the striatum","volume":"28","author":"Bonsi","year":"2008","journal-title":"J Neurosci"},{"key":"10.1016\/j.biopsych.2025.10.013_bib62","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1038\/npp.2015.65","article-title":"TAAR1 modulates cortical glutamate NMDA receptor function","volume":"40","author":"Espinoza","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2025.10.013_bib63","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/mp.2012.57","article-title":"A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight","volume":"18","author":"Revel","year":"2013","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2025.10.013_bib64","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40035-017-0076-6","article-title":"Imaging biomarkers in Parkinson\u2019s disease and Parkinsonian syndromes: Current and emerging concepts","volume":"6","author":"Saeed","year":"2017","journal-title":"Transl Neurodegener"},{"key":"10.1016\/j.biopsych.2025.10.013_bib65","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1001\/jamapsychiatry.2017.0135","article-title":"Association of stimulant use with dopaminergic alterations in users of cocaine, amphetamine, or methamphetamine: A systematic review and meta-analysis","volume":"74","author":"Ashok","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.biopsych.2025.10.013_bib66","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.euroneuro.2022.12.008","article-title":"The substantia nigra in the pathology of schizophrenia: A review on post-mortem and molecular imaging findings","volume":"68","author":"van Hooijdonk","year":"2023","journal-title":"Eur Neuropsychopharmacol"},{"issue":"suppl 2","key":"10.1016\/j.biopsych.2025.10.013_bib67","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1016\/j.parkreldis.2008.04.006","article-title":"Trace amine associated receptor 1 and movement control","volume":"14","author":"Sotnikova","year":"2008","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.biopsych.2025.10.013_bib68","doi-asserted-by":"crossref","first-page":"14057","DOI":"10.1523\/JNEUROSCI.1312-15.2015","article-title":"Modulation by trace amine-associated receptor 1 of experimental Parkinsonism, l-DOPA responsivity, and glutamatergic neurotransmission","volume":"35","author":"Alvarsson","year":"2015","journal-title":"J Neurosci"},{"key":"10.1016\/j.biopsych.2025.10.013_bib69","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41582-023-00904-0","article-title":"Schizophrenia: From neurochemistry to circuits, symptoms and treatments","volume":"20","author":"Howes","year":"2024","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.biopsych.2025.10.013_bib70","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1177\/02698811221122031","article-title":"The effect of AUT00206, a Kv3 potassium channel modulator, on dopamine synthesis capacity and the reliability of [18F]-FDOPA imaging in schizophrenia","volume":"36","author":"Angelescu","year":"2022","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.biopsych.2025.10.013_bib71","doi-asserted-by":"crossref","first-page":"7082","DOI":"10.1021\/acs.jmedchem.4c02291","article-title":"Rational design of the first dual agonist at trace amine-associated receptor 1 and 5-HT2C receptors based on binding pocket similarity for the treatment of schizophrenia and Alzheimer\u2019s disease-related psychosis","volume":"68","author":"Lu","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.biopsych.2025.10.013_bib72","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adn1524","article-title":"AlphaFold accelerated discovery of psychotropic agonists targeting the trace amine\u2013associated receptor 1","volume":"10","author":"D\u00edaz-Holgu\u00edn","year":"2024","journal-title":"Sci Adv"},{"key":"10.1016\/j.biopsych.2025.10.013_bib73","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1017\/S1461145709990599","article-title":"Antipsychotic drug-induced increases in ventral tegmental area dopamine neuron population activity via activation of the nucleus accumbens-ventral pallidum pathway","volume":"13","author":"Valenti","year":"2010","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.biopsych.2025.10.013_bib74","doi-asserted-by":"crossref","first-page":"5068","DOI":"10.1523\/JNEUROSCI.18-13-05068.1998","article-title":"Striatal extracellular dopamine levels in rats with haloperidol-induced depolarization block of substantia nigra dopamine neurons","volume":"18","author":"Moore","year":"1998","journal-title":"J Neurosci"},{"key":"10.1016\/j.biopsych.2025.10.013_bib75","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/s41586-023-06804-z","article-title":"Ligand recognition and G-protein coupling of trace amine receptor TAAR1","volume":"624","author":"Xu","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.biopsych.2025.10.013_bib76","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/s41586-023-06775-1","article-title":"Recognition of methamphetamine and other amines by trace amine receptor TAAR1","volume":"624","author":"Liu","year":"2023","journal-title":"Nature"}],"container-title":["Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322325015331?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322325015331?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T09:23:30Z","timestamp":1782293010000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006322325015331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":76,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0006322325015331"],"URL":"https:\/\/doi.org\/10.1016\/j.biopsych.2025.10.013","relation":{},"ISSN":["0006-3223"],"issn-type":[{"value":"0006-3223","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TAAR1 Regulates Presynaptic Dopamine Function: Evidence From Preclinical Studies and a Phase 1b Trial in Patients With Schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopsych.2025.10.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Society of Biological Psychiatry.","name":"copyright","label":"Copyright"}]}}